Science Immunology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2026-03-08 ms4000001372840083 来自丹麦

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：inflammation;cell signaling;Innate immunity
经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer.

81 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2025-07-14 记录投稿经历来自广东省

各位大佬，有投Science Translational Medicine让转投这个杂志的吗

105 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2022-10-20 csw1314527

偏重的研究方向：innate immunity
经验分享：under evaluation 两周了，请问下大神这是什么情况

289 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2024-08-23 朋友一场来自北京

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：免疫学
经验分享：8月20 submited
8月23 To advisor
等待中。。。

154 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2023-04-07 ms7000001335611101 来自天津

偏重的研究方向：免疫学
经验分享：投稿分享 4-4投稿 4-5 Under Evaluation

288 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2022-02-26 MAC1234

审稿速度:3.0
经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过

317 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2022-09-06 guolihuihelan_91618321

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：covid-19
经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看

289 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2022-02-18 ms1000001479366679

审稿速度:6.0
经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？

276 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2020-10-11 charlene0316

editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭

504 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2302791, encodeId=71712302e91f3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：inflammation;cell signaling;Innate immunity 经验分享：Transferred from Science together with the review comments and point-by-point response, as the Science editor explained that they only consider manuscripts with positive comments from all four reviewers. The manuscript proceeded directly to a second round of review with the same reviewers at Science Immunology. After several rounds of revision, it was accepted roughly 8 months after transfer. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90a9577136, createdName=ms4000001372840083, createdTime=Sun Mar 08 04:23:24 CST 2026, time=2026-03-08, status=1, ipAttribution=丹麦), GetPortalCommentsPageByObjectIdResponse(id=2273302, encodeId=39ea22e330296, content=各位大佬，有投Science Translational Medicine让转投这个杂志的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Mon Jul 14 13:53:37 CST 2025, time=2025-07-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2094920, encodeId=ed5e20949206d, content=偏重的研究方向：innate immunity 经验分享：under evaluation 两周了，请问下大神这是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94692322786, createdName=csw1314527, createdTime=Thu Oct 20 10:36:26 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2222035, encodeId=bc1322220351f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：8月20 submited 8月23 To advisor 等待中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Fri Aug 23 12:17:50 CST 2024, time=2024-08-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2124248, encodeId=92c3212424872, content=偏重的研究方向：免疫学 经验分享：投稿分享 4-4投稿 4-5 Under Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Apr 07 09:48:27 CST 2023, time=2023-04-07, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1197594, encodeId=b8a5119e594a0, content=审稿速度:3.0 经验分享：投稿science immunology两个多月了一直是under evaluation，发了N封邮件都不回，打电话也没人接，终于有一天有个editor回了我说正在等待评估，心中一万只草泥马奔腾而过, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220118/84bf90008eb14883a640399b24452658/54a21c2bbe124b718a975508d9cb80bf.jpg, createdBy=0f5b5624592, createdName=MAC1234, createdTime=Sat Feb 26 21:34:41 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243407, encodeId=8e99124340eb6, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：covid-19 经验分享：这个月准备投，先来拜个山头，等接受了，再回来看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Sep 06 01:23:45 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194777, encodeId=71d81194e7779, content=审稿速度:6.0 经验分享：投稿3个月了邮件问说还在初步审稿没送审，速度很慢呀有没有其他的朋友有类似的经历？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b6215509368, createdName=ms1000001479366679, createdTime=Fri Feb 18 12:02:50 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891178, encodeId=579a8911e810, content=editor assigned一个多月了还在under evaluation，有没有也是这样的，是不是editor太忙忘记了，发了两次邮件也没回😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a931717656, createdName=charlene0316, createdTime=Sun Oct 11 00:13:56 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916247, encodeId=9c0391624e5b, content=收不收综述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Wed Jan 13 15:39:06 CST 2021, time=2021-01-13, status=1, ipAttribution=)]

2021-01-13 丿柚子

收不收综述？

341 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务